ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
World Health Organization, 2015. Guidelines for the Treatment of Malaria, 3rd edition. Geneva, Switzerland: World Health Organization. Available at: http://www.who.int/malaria/publications/atoz/9789241549127/en/. Accessed March 17, 2016.
-
2.
Pukrittayakamee S, Chantra A, Vanijanonta S, Clemens R, Looareesuwan S, White NJ, 2000. Therapeutic responses to quinine and clindamycin in multidrug-resistant falciparum malaria. Antimicrob Agents Chemother 44: 2395–2398.
-
3.
Fungladda W, Honrado ER, Thimasarn K, Kitayaporn D, Karbwang J, Kamolratanakul P, Masngammueng R, 1998. Compliance with artesunate and quinine + tetracycline treatment of uncomplicated falciparum malaria in Thailand. Bull World Health Organ 76 (Suppl 1): 59–66.
-
4.
Ramharter M, Oyakhirome S, Klein Klouwenberg P, Adegnika AA, Agnandji ST, Missinou MA, Matsiegui PB, Mordmuller B, Borrmann S, Kun JF, Lell B, Krishna S, Graninger W, Issifou S, Kremsner PG, 2005. Artesunate-clindamycin versus quinine-clindamycin in the treatment of Plasmodium falciparum malaria: a randomized controlled trial. Clin Infect Dis 40: 1777–1784.
-
5.
Lell B, Kremsner PG, 2002. Clindamycin as an antimalarial drug: review of clinical trials. Antimicrob Agents Chemother 46: 2315–2320.
-
6.
Salman S, Rogerson SJ, Kose K, Griffin S, Gomorai S, Baiwog F, Winmai J, Kandai J, Karunajeewa HA, O'Halloran SJ, Siba P, Ilett KF, Mueller I, Davis TM, 2010. Pharmacokinetic properties of azithromycin in pregnancy. Antimicrob Agents Chemother 54: 360–366.
-
7.
Chandra RS, Orazem J, Ubben D, Duparc S, Robbins J, Vandenbroucke P, 2013. Creative solutions to extraordinary challenges in clinical trials: methodology of a phase III trial of azithromycin and chloroquine fixed-dose combination in pregnant women in Africa. Malar J 12: 122.
-
8.
Moore BR, Benjamin JM, Auyeung SO, Salman S, Yadi G, Griffin S, Page-Sharp M, Batty KT, Siba PM, Mueller I, Rogerson SJ, Davis TM, 2016. Safety, tolerability and pharmacokinetic properties of co-administered azithromycin and piperaquine in pregnant Papua New Guinean women. Br J Clin Pharmacol. doi:10.1111/bcp.12910. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26889763. Accessed March 17, 2016.
-
9.
Unger HW, Ome-Kaius M, Wangnapi RA, Umbers AJ, Hanieh S, Suen CS, Robinson LJ, Rosanas-Urgell A, Wapling J, Lufele E, Kongs C, Samol P, Sui D, Singirok D, Bardaji A, Schofield L, Menendez C, Betuela I, Siba P, Mueller I, Rogerson SJ, 2015. Sulphadoxine-pyrimethamine plus azithromycin for the prevention of low birthweight in Papua New Guinea: a randomised controlled trial. BMC Med 13: 9.
-
10.
Thanh NX, Trung TN, Phong NC, Quang HH, Dai B, Shanks GD, Chavchich M, Edstein MD, 2012. The efficacy and tolerability of artemisinin-piperaquine (Artequick®) versus artesunate-amodiaquine (Coarsucam™) for the treatment of uncomplicated Plasmodium falciparum malaria in south-central Vietnam. Malar J 11: 217.
-
11.
Thanh NV, Toan TQ, Cowman AF, Casey GJ, Phuc BQ, Tien NT, Hung NM, Biggs BA, 2010. Monitoring for Plasmodium falciparum drug resistance to artemisinin and artesunate in Binh Phuoc Province, Vietnam: 1998–2009. Malar J 9: 181.
-
12.
Thanh NX, Trung TN, Phong NC, Thien NX, Dai B, Shanks GD, Chavchich M, Edstein MD, 2009. Open label randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in central Vietnam. Trop Med Int Health 14: 504–511.
-
13.
Padley D, Moody AH, Chiodini PL, Saldanha J, 2003. Use of a rapid, single-round, multiplex PCR to detect malarial parasites and identify the species present. Ann Trop Med Parasitol 97: 131–137.
-
14.
World Health Organization, 2008. Methods and Techniques for Clinical Trials on Antimalarial Drug Efficacy: Genotyping to Identify Parasite Populations. Geneva. Switzerland: World Health Organization. Available at: http://apps.who.int/iris/bitstream/10665/43824/1/9789241596305_eng.pdf. Accessed March 17, 2016.
-
15.
Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, Kim S, Duru V, Bouchier C, Ma L, Lim P, Leang R, Duong S, Sreng S, Suon S, Chuor CM, Bout DM, Menard S, Rogers WO, Genton B, Fandeur T, Miotto O, Ringwald P, Le Bras J, Berry A, Barale JC, Fairhurst RM, Benoit-Vical F, Mercereau-Puijalon O, Menard D, 2014. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505: 50–55.
-
16.
Price R, van Vugt M, Phaipun L, Luxemburger C, Simpson J, McGready R, ter Kuile F, Kham A, Chongsuphajaisiddhi T, White NJ, Nosten F, 1999. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am J Trop Med Hyg 60: 547–555.
-
17.
Flegg JA, Guerin PJ, White NJ, Stepniewska K, 2011. Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J 10: 339.
-
18.
Sidhu AB, Sun Q, Nkrumah LJ, Dunne MW, Sacchettini JC, Fidock DA, 2007. In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. J Biol Chem 282: 2494–2504.
-
19.
Chinh NT, Quang NN, Anh CX, Thanh NX, Dai B, Birrell GW, Chavchich M, Edstein MD, 2011. Pharmacokinetics and ex vivo antimalarial activity of artesunate-azithromycin in healthy volunteers. Antimicrob Agents Chemother 55: 4412–4415.
-
20.
Thriemer K, Starzengruber P, Khan WA, Haque R, Marma AS, Ley B, Vossen MG, Swoboda P, Akter J, Noedl H, 2010. Azithromycin combination therapy for the treatment of uncomplicated falciparum malaria in Bangladesh: an open-label randomized, controlled clinical trial. J Infect Dis 202: 392–398.
-
21.
Noedl H, Krudsood S, Chalermratana K, Silachamroon U, Leowattana W, Tangpukdee N, Looareesuwan S, Miller RS, Fukuda M, Jongsakul K, Sriwichai S, Rowan J, Bhattacharyya H, Ohrt C, Knirsch C, 2006. Azithromycin combination therapy with artesunate or quinine for the treatment of uncomplicated Plasmodium falciparum malaria in adults: a randomized, phase 2 clinical trial in Thailand. Clin Infect Dis 43: 1264–1271.
-
22.
Sykes A, Hendriksen I, Mtove G, Mandea V, Mrema H, Rutta B, Mapunda E, Manjurano A, Amos B, Reyburn H, Whitty CJ, 2009. Azithromycin plus artesunate versus artemether-lumefantrine for treatment of uncomplicated malaria in Tanzanian children: a randomized, controlled trial. Clin Infect Dis 49: 1195–1201.
-
23.
Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ, 2009. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361: 455–467.
-
24.
Hien TT, Thuy-Nhien NT, Phu NH, Boni MF, Thanh NV, Nha-Ca NT, Thai le H, Thai CQ, Toi PV, Thuan PD, Long le T, Dong le T, Merson L, Dolecek C, Stepniewska K, Ringwald P, White NJ, Farrar J, Wolbers M, 2012. In vivo susceptibility of Plasmodium falciparum to artesunate in Binh Phuoc Province, Vietnam. Malar J 11: 355.
-
25.
World Health Organization, 2014. World Malaria Report 2014. Geneva, Switzerland: World Health Organization. Available at: http://www.who.int/malaria/publications/world_malaria_report_2014/en/. Accessed March 17, 2016.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 0 | 0 | 0 |
| Full Text Views | 267 | 99 | 1 |
| PDF Downloads | 72 | 24 | 1 |
In Vivo Efficacy and Tolerability of Artesunate–Azithromycin for the Treatment of Falciparum Malaria in Vietnam
Safe and effective antimalarial drugs are required for the treatment of pregnant women. We report a 3-day regimen of artesunate (4 mg/kg/day)–azithromycin (25 mg/kg/day) (ASAZ) to be efficacious (polymerase chain reaction–corrected cure rate of 96.7%) and well tolerated in the treatment of Plasmodium falciparum malaria in children (N = 11) and adults (N = 19), in Vietnam in 2010. In comparison, the cure rate for artesunate (4 mg/kg on day 0, 2 mg/kg on days 1–6) was 90.0% in children (N = 7) and adults (N = 23). Because azithromycin is considered safe in pregnancy, our findings provide further evidence that ASAZ should be evaluated for the treatment of pregnant women with malaria.
Author Notes
Authors' addresses: Nguyen Chinh Phong, Nguyen Xuan Thanh, and Bui Dai, Malaria Department, Military Institute of Preventive Medicine, Hanoi, Vietnam, E-mails: mp.impe@gmail.com, nxthanhvspdqd@yahoo.com, and buidai2003@yahoo.com. Huynh Hong Quang and Trieu Nguyen Trung, Malaria Department, Institute of Malariology, Parasitology and Entomology, Quy Nhon, Vietnam, E-mails: huynhquangimpe@yahoo.com and trieutrung@dnn.vnn.vn. G. Dennis Shanks, Marina Chavchich, and Michael D. Edstein, Department of Drug Evaluation, Australian Army Malaria Institute, Brisbane, Australia, E-mails: dennis.shanks@defence.gov.au, marina.chavchich@defence.gov.au, and mike.edstein@defence.gov.au.